R&D News | pharmaphorum

News

Mariana Oncology's chief executive Simon Read

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Onc

News

Dr Elias Sayour, Chong Zhao and Arnav Barpujari discuss the mRNA cancer vaccine developed at the University of Florida

RNA glioblastoma vaccine shows promise in first human trial

A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial.

News

Astellas expands Poseida alliance on solid tumour CAR-Ts

Astellas has clearly been impressed with a partnership signed last August with Poseida Therapeutics on the development of cell therapies for solid tumours, as it has just

News

Jacobio plans bid for China’s KRAS market with safety edge

Jacobio Pharma has reported the results of its pivotal Chinese study of KRAS G12C inhibitor glecirasib, with a safety profile that could differentiate it from other drugs

News

Biotts claims a first with insulin delivery across skin

Polish drug delivery company Biotts says it has demonstrated delivery of insulin across the skin for the first time without the use of an injection system.

News

Prime editing comes of age as FDA clears human trials

Prime Medicine has been given the go-ahead by the FDA for the first human trial of its prime editing technology, which promises to deliver one-shot therapies for a range o

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

RNA glioblastoma vaccine shows promise in first human trial

Astellas expands Poseida alliance on solid tumour CAR-Ts

Jacobio plans bid for China’s KRAS market with safety edge

Biotts claims a first with insulin delivery across skin

Prime editing comes of age as FDA clears human trials

Italy leads the way on child genetic disease diagnosis

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks